108 results on '"Arzeni, D."'
Search Results
2. Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years
3. Electrophoretic Karyotyping and Triazole Susceptibility of Candida glabrata Clinical Isolates
4. In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinical isolates of Candida spp.
5. In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes
6. In vitro activity of the lipopeptide derivative (Pal-lys-lys-NH2), alone and in combination with antifungal agents, against clinical isolates of dermatophytes
7. Genotypic identification of sequentialCandida albicans isolates from AIDS patients by polymerase chain reaction techniques
8. Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections
9. In vitro activity of terbinafine against clinical isolates of dermatophytes
10. Genotypic identification of sequential Candida albicans isolates from AIDS patients by polymerase chain reaction techniques
11. Trichosporon beigelii fungaemia in an AIDS patient
12. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer
13. Caratterizzazione dell'attività anticriptococcica di un nuovo derivato pirazoloisotiazolico
14. In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection
15. In vitroactivity of the lipopeptide derivative (Pal-lys-lys-NH2), alone and in combination with antifungal agents, against clinical isolates of dermatophytes
16. In vitro activity of terbinafine against clinical isolates of dermatophytes
17. In-VitroActivity of the Synthetic Protegrin IB-367 Alone and in Combination with Antifungal Agents Against Clinical Isolates ofCandidaspp.
18. Fluconazole Susceptibility ofCandidaspp. Isolates Collected Over Nine Years in a Teaching Hospital of Ancona, Italy
19. Genotyping and antifungal susceptibility of human subgingival Candida albicans isolates
20. Primary resistance to flucytosine among clinical isolates of Candida spp.
21. Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot
22. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans
23. Comparison of Broth Dilution and Semisolid Agar Dilution forIn VitroSusceptibility Testing ofCryptococcus neoformans
24. Fluconazole and Ketoconazole in the Treatment of Oral and Esophageal Candidiasis in AIDS Patients
25. In vitro activity of the lipopeptide derivative (Pal-lys-lys-NH2), alone and in combination with antifungal agents, against clinical isolates of dermatophytes.
26. Fluconazole, Itraconazole and KetoconazoleIn- VitroActivity. A Comparative Study
27. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans.
28. Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis.
29. Genotypic identification of sequentialCandida albicansisolates from AIDS patients by polymerase chain reaction techniques
30. In vitroactivity of terbinafine against clinical isolates of dermatophytes
31. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer
32. Antimicrobial Activity of Different Antimicrobial Peptides (AMPs) Against Clinical Methicillin-resistant Staphylococcus aureus (MRSA).
33. TRAP1 controls cell migration of cancer cells in metabolic stress conditions: Correlations with AKT/p70S6K pathways.
34. In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes.
35. An atypical, pigment-producing Metschnikowia strain from a leukaemia patient.
36. Intestinal parasitosis: data analysis 2006-2011 in a teaching hospital of Ancona, Italy.
37. In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents.
38. In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp.
39. In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans.
40. Fluconazole susceptibility of Candida spp. isolates collected over nine years in a teaching hospital of Ancona, Italy.
41. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.
42. Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata.
43. Caspofungin in combination with amphotericin B against Candida glabrata.
44. Sequential therapy with caspofungin and fluconazole for Candida albicans infection.
45. Antifungal susceptibility patterns of yeast isolates causing bloodstream infections.
46. In vitro and in vivo anticryptococcal activities of a new pyrazolo-isothiazole derivative.
47. Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy.
48. In vitro activity of posaconazole against clinical isolates of dermatophytes.
49. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
50. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.